Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized, multiple-dose and single-dose crossover, 2-part study to evaluate safety, tolerability and pharmacokinetics of injectable WCK 4282 (FEP-TAZ) in healthy male and female subjects.

Trial Profile

A double-blind, randomized, multiple-dose and single-dose crossover, 2-part study to evaluate safety, tolerability and pharmacokinetics of injectable WCK 4282 (FEP-TAZ) in healthy male and female subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cefepime/tazobactam (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 May 2017 New trial record
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top